Oxxon Therapeutics
Trademark details
Oxxon Therapeutics® is a registered trademark used for Pharmaceutical Preparations For the Treatment and Prevention of Cancer, Hepatitis, Aids, Malaria, Influenza, Epstein-Bar Virus, Measles, Tuberculosis, Toxoplasmosis, Herpes, Melanomas and Infectious Diseases In General and owned by Oxxon Pharmaccines Limited. Full trade mark registration details, registered images and more information below.
| Goods and/or Services: | Pharmaceutical Preparations For the Treatment and Prevention of Cancer, Hepatitis, Aids, Malaria, Influenza, Epstein-Bar Virus, Measles, Tuberculosis, Toxoplasmosis, Herpes, Melanomas and Infectious Diseases In General Vaccines For the Treatment and Prevention of Cancer, Hepatitis, Aids, Malaria, Influenza, Epstein-Bar Virus, Measles, Tuberculosis, Toxoplasmosis, Herpes, Melanomas and Infectious Diseases In General Biological Preparations For the Treatment and Prevention of Cancer, Hepatitis, Aids, Malaria, Influenza, Epstein-Bar Virus, Measles, Tuberculosis, Toxoplasmosis, Herpes, Melanomas and Infectious Diseases In General Electronic Publications, Namely, Books, Magazines, Manuals, Newsletters, Brochures, Pamphlets, Periodicals Featuring Information In the Field of Scientific Research, Health Care Maintenance, Clinical Research, Disease Management and Pharmaceutical Issues Recorded On Cd Roms, Optical Discs, Dvds and Downloadable From a Global Communications Network Printed Publications In the Field of Scientific Research, Health Care Maintenance, Clinical Research, Disease Management and Pharmaceutical Issues, Namely, Books, Booklets, Newsletters, Brochures, Magazines and Manuals Stationery Scientific Research Consultancy In the Field of Scientific Research Providing Information Relating To Scientific Research Product Research and Development For Others |
| Serial Number: | 79003837 |
| Registration Number: | 3018090 |
| Filing Date: | Apr 28, 2004 |
|
Last Applicant(s)/ Owner(s) of Record | Oxxon Pharmaccines Limited2nd Floor, Florey House |
| Related Products: | Pharmaceuticals, Electrical and Scientific Apparatus, Paper Goods and Printed Matter, Miscellaneous Services; Scientific and technological services, and research and design relating thereto; Industrial analysis and research services; Design and development of computer hardware and software; Legal services |
Suppliers
Total : 2 View more »
Oxxon Therapeutics Inc in Boston, Massachusetts, USA
Edit this Company edit this company Oxxon Therapeutics Inc Old City Hall 45 Schl St Boston, Massachusetts 02108 USA tel: +1 6173832100 Description Commercial Physical...
Oxxon Therapeutics Ltd in Oxford, Oxfordshire, United Kingdom
Edit this Company edit this company Oxxon Therapeutics Ltd 2nd Floor Florey House 3 Robert Robinson Avenue Oxford, Oxfordshire OX4 4GP United Kingdom tel: +44 1865398100...
Web Sites
powered by 
Total : 27,600 View more »
Oxxon Therapeutics Ltd - An Isis Innovation Spin-out
Oxxon Therapeutics - acquired by oxford biomedica plc . www.oxfordbiomedica.com. the company was spun-out from the Nuffield Department of Clinical Medicine at the ...
Oxxon Therapeutics Ltd Launches U S Operation A
OXFORD, England, and BOSTON, April 13 /PRNewswire/ -- Oxxon Therapeutics Ltd , a biotechnology company developing immunotherapeutics for cancer and
Oxxon Therapeutics Ltd.: Private Company Information - Businessweek
Oxxon Therapeutics Ltd. company research & investing information. Find executives and the latest company news.
Oxxon Therapeutics Inc HI 8TM HBV Therapeutic
OXFORD, April 27 /PRNewswire/ -- Oxxon Therapeutics today presented efficacy data from the recently completed Phase IIa clinical study of its novel
Web Sites
Total : 2 View more »
doi:10.1016/S0140-6736(04)16367-8
...although such responses have not been directly explored for rabies glycoprotein. I own a small number of shares in Oxxon Therapeutics, who own the DNA prime MVA boost CTL patent, as a consequence of being a named inventor. I have no other role...
doi:10.1016/S0140-6736(04)16369-1
...although such responses have not been directly explored for rabies glycoprotein. I own a small number of shares in Oxxon Therapeutics, who own the DNA prime MVA boost CTL patent, as a consequence of being a named inventor. I have no other role...
News and Blogs
Total : 2 View more »
News: Oxford BioMedica Picks Up Oxxon in $38.8M Transaction.
...BioMedica Picks Up Oxxon in $38.8M Transaction GEN News Highlights Oxford BioMedica plans to acquire Oxxon Therapeutics in a stock-for-stock transaction valued at GBP16 million, or over $38.8 million. Oxford BioMedica is...
Rabies and other lyssavirus diseases : The Lancet
...although such responses have not been directly explored for rabies glycoprotein. I own a small number of shares in Oxxon Therapeutics, who own the DNA prime MVA boost CTL patent, as a consequence of being a named inventor. I have no other role...
Explore Related Topics:
Related Products:
